Paul Isaac
Arbiter Partners Capital Management
Paul Isaac Atrium Therapeutics, Inc stake
total: 298
Arbiter Partners Capital Management RNA trades
- Total transactions:
- 2
- New positions:
- 1
- Added:
- 1
- Held since:
- 2026 Q1
- Held for:
- 2 quarters
- Latest activity:
- 2026 Q2
According to 2026 Q2 report, Paul Isaac holds 261,288 Atrium Therapeutics, Inc (RNA) shares with a market value of roughly $3.51M accounting for 1.95% of the overall portfolio. To date, the estimated cost basis is nearly $13.38 for "buy" trades. Arbiter Partners Capital Management first purchased RNA in 2026 Q1, initially acquiring 230,000 shares. Since the initial investment in Atrium Therapeutics, Inc (RNA), Arbiter Partners Capital Management has made 1 more transaction.
When did Paul Isaac buy Atrium Therapeutics, Inc (RNA)?
Paul Isaac first invested in Atrium Therapeutics, Inc (RNA) in 2026 Q1 at the reported quarter-end price of $13.37 per share.
What's the cost basis of Arbiter Partners Capital Management's RNA stake?
The estimated cost basis for Atrium Therapeutics, Inc (RNA) stake is around $13.38 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $13.38
Paul Isaac's historical trades in Atrium Therapeutics, Inc
2 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q2
|
1.95%
|
261,288
|
$13.45
|
$3,514,324
|
+13.60% (+31,288)
|
+0.23%
|
|
2026 Q1
|
2.09%
|
230,000
|
$13.37
|
$3,075,100
|
new
|
+2.09%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.